A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.
ECOG PS, Eastern Cooperative Oncology Group performance status
ICI, Immune checkpoint inhibitors
Radiation therapy
Radio-insensitive
Right heart failure
SD-TSTs, SMARCA4-deficient thoracic sarcomatoid tumors
SMARCA4
SMARCA4-DTC, SMARCA4-deficient thoracic undifferentiated carcinoma
SMARCA4-Deficient thoracic undifferentiated carcinoma
SWI/SNF, switch/sucrose non-fermentable
Sarcomatoid tumor
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
12
2020
revised:
09
01
2021
accepted:
13
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
SMARCA4-deficient thoracic sarcomatoid tumors were characterized by inactivating mutations of SMARCA4 and often found in the chest of young and middle-aged males with a smoking history. Recently, SMARCA4-deficient thoracic sarcomatoid tumors were reported to represent primarily smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic sarcomas. The main complication of this tumor is compression of the respiratory tract and/or blood vessels. A 39-year-old man presented with a 2-month history of fever and dyspnea. Computed tomography revealed a mediastinal tumor invading the right and left pulmonary arteries. Because of severe right heart failure, we considered him ineligible for bronchoscopy. We scheduled palliative irradiation with 40 Gy/20 Fr to improve hemodynamics and perform endobronchial ultrasound transbronchial needle aspiration later. However, irradiation was ineffective, and his general condition deteriorated quickly and he died after a 7-week hospitalization. An autopsy revealed that the diagnosis was SMARCA4-deficient thoracic undifferentiated carcinoma. It has been reported that this tumor is insensitive to radiotherapy and there were some cases which responded to an immune checkpoint inhibitor. Therefore, when caring for patients with mediastinal tumors that invade and compress the trachea and large vessels, it is important to consider this tumor as a differential diagnosis and try to make a pathological diagnosis as soon as possible.
Identifiants
pubmed: 33665078
doi: 10.1016/j.rmcr.2021.101364
pii: S2213-0071(21)00026-5
pmc: PMC7906892
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101364Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Authors declare that they have no conflict of interest.
Références
Lancet Respir Med. 2020 Sep;8(9):895-904
pubmed: 32199466
Nat Rev Cancer. 2004 Feb;4(2):133-42
pubmed: 14964309
Eur Radiol. 2019 Sep;29(9):4730-4741
pubmed: 30762113
Niger J Clin Pract. 2019 Mar;22(3):342-349
pubmed: 30837421
Nat Genet. 2015 Oct;47(10):1200-5
pubmed: 26343384
Am J Surg Pathol. 2019 Apr;43(4):455-465
pubmed: 30451731
J Comput Assist Tomogr. 2004 Nov-Dec;28(6):782-9
pubmed: 15538151
Mod Pathol. 2017 Jun;30(6):797-809
pubmed: 28256572
J Thorac Oncol. 2020 Feb;15(2):231-247
pubmed: 31751681
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Nat Rev Cancer. 2011 Jun 09;11(7):481-92
pubmed: 21654818
Ann Oncol. 2019 Aug 1;30(8):1401-1403
pubmed: 31114851